LCx was compared to other assays in measuring human immunodeficiency virus type 1 (HIV-1) CRF02 viremia. LCx showed significant but low correlation with the other methods. Values of <2.60 log 10 cp/ml were observed in 29.6% of specimens with LCx and in only 14.8% with bDNA and PCR, suggesting suboptimal performance of LCx with CRF02.
Clinical management of human immunodeficiency virus type1 (HIV-1) infection and implementation of treatment strategies rely on routine measurement of levels of HIV-1 RNA in plasma (23, 24) . A variety of commercial assays, employing different molecular technologies, are available for measuring HIV-1 RNA levels in plasma. They differ in sensitivity, dynamic range, target region, and methods of nucleic acid detection (15, 16, 18, 25) .
Most of these assays have been optimized for the detection of subtype B of HIV-1 (13) , which predominates in the United States and Europe. However, increasing numbers of non-subtype-B infections are being identified in Europe (1, 4, 9, 12, 17) and the United States (6, 22) . In developing countries, non-B strains are widespread and often predominant (20) .
Therefore, it is important that viral load (VL) assays detect and accurately quantify all the known HIV-1 subtypes, intersubtype recombinants, and emerging variants to avoid underquantification or even complete lack of detection. HIV-1 sequence variation within target regions used for VL quantification can directly impact the performance of diagnostic assays (2, 21) .
It has been reported that some commercial assays either underevaluate or fail to detect HIV RNA subtypes A, E, and G and other minor strains (7, 8, 10, 11, 14, 19) . Poor performance of the NucliSens HIV RNA QT assay in quantifying viremia for the circulating recombinant form of HIV-1 A/G (CRF02) has been recently described (3, 27 a At the time of blood sampling, all patients were naive for antiviral treatment; three of them were under treatment with two nucleoside analogs or two nucleoside analogs plus a protease inhibitor.
b Patient under treatment at the time of blood sampling. Isolates from all the patients had their HIV genotype assignment based on the nucleotide sequence of gag and/or pol regions, as described previously (3) . The patients were all in the chronic phase of the infection, and most of them had not been treated by the time of sampling (Table 1) . Each patient was sampled once, and all specimens were tested once. Assays were conducted in parallel with an external subtype B standard (Pelyspy-97; CLB Viral Diagnostic Laboratory, Amsterdam, The Netherlands). Individual values obtained by the four assays are reported in Table 1 . Plasma HIV-1 RNA levels were log 10 transformed before being subjected to statistical analysis. Values were compared by nonparametric tests, as indicated. Data were also analyzed by plotting the difference between measurements obtained by two methods against their average, to assess the correlation between this difference and the magnitude of measurement (5). Furthermore, individual values obtained in different assays underwent linear regression analysis, and Pearson's correlation coefficient (r) was calculated. To avoid biases in statistical analyses because of the difference in the lower limits of detection (LLD) of the assays, all samples with HIV RNA levels undetectable by Amplicor, or Ͻ2.60 log 10 copies (cp)/ml by the bDNA, LCx, and NASBA methods, were assigned the value of the Amplicor LLD, i.e., 2.60 log 10 cp/ml.
The mean values of VL, obtained by the four assays with the whole group of samples harboring HIV-1 CRF02, were statistically different (Friedman test, P Ͻ 0.001): 4.21 Ϯ 1.07 log 10 cp/ml by Amplicor, 3.98 Ϯ 0.89 log 10 cp/ml by Versant, 3.58 Ϯ 0.90 log 10 cp/ml by LCx, and 3.21 Ϯ 0.80 log 10 cp/ml by NucliSens. Mean values obtained by LCx were significantly different from those obtained Amplicor but not from those obtained by Versant and Nuclisens (Wilcoxon sign rank test, P ϭ 0.004, P ϭ 0.184, and P ϭ 0.069, respectively).
Comparisons conducted according by the method of Bland and Altman (5) showed that in Nuclisens-Amplicor and Versant-Amplicor comparisons, absolute values of difference with respect to average values, between the members of each paired value, significantly increased with the magnitude of VL (r ϭ Ϫ0.324 and P ϭ 0.022, and r ϭ Ϫ0.197 and P ϭ 0.045, respectively) (Fig. 1) . The other pairs of methods considered did not show such a trend, indicating a constant difference in measuring VL.
When paired values obtained for each sample was compared by using different assays were compared the correlation was significant for each pair of assays considered (Fig. 2) . However, Amplicor and Versant showed the highest correlation coefficient (r ϭ 0.894 and p Ͻ 0.001), while the correlation coefficients involving LCx and the other assays were notably lower: r ϭ 0.334 and P ϭ 0.088 for LCx-Nuclisens, r ϭ 0.431 and P ϭ 0.025 for LCx-Amplicor, and r ϭ 0.464 and P ϭ 0.015 for LCx-Versant.
The proportion of samples with values of Յ2.60 log 10 cp/ml was different among the assays (P ϭ 0.015 by the Cochran test): only 4 (14.8%) of 27 samples were undetectable by Amplicor and Versant, while 8 (29.6%) and 11 (40.7%) samples were undetectable by LCx and Nuclisens, respectively. The proportion of samples with undetectable VL was significantly different when considering Nuclisens-Versant and NuclisensAmplicor (P ϭ 0.016 by the McNemar test), as expected, while for LCx-Versant, LCx-Amplicor, and LCx-Nuclisens the differences were not statistically significant (P ϭ 0.219, P ϭ 0.289, and P ϭ 0.508, respectively). The values of the kappa statistic were lower for pairwise comparisons involving LCx (0.279 and P ϭ 0.135 for LCx-Nuclisens, 0.169 and P ϭ 0.334 for LCxAmplicor, and 0.337 and P ϭ 0.031 for LCx-Versant) than in the other cases (0.413 and P ϭ 0.032 for Amplicor-Versant, and 0.404 and P ϭ 0.009 for Amplicor-Nuclisens and VersantNuclisens).
Samples from patients infected with HIV-1 subtype B were also analyzed. All assays gave comparable results, with an excellent correlation among the methods (data not shown), thus confirming high performance and strong correlation of all these methods in detecting subtype B.
Although the LCx assay employs primers targeting a specific and highly conserved sequence in the pol region, ensuring consistent results for all HIV-1 M and O subtypes (26) , this study demonstrated a certain degree of inability to efficiently quantificate VL from CRF02. This inability is less pronounced than that previously demonstrated for Nuclisens (27) . Although the number of samples used in this study is small, these results can have important implications. In fact, measurement of VL is a key issue in clinical management of HIV-1-infected patients. Since infections by non-B strains and intersubtype recombinant forms of HIV-1 are spreading worldwide, it will be worthwhile to extend our observation to other circulating non-B HIV-1 subtypes in order to obtain information about the actual performance of VL assays, particularly in respect to their use in developing countries.
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